drugset / Trial / NCT02223000

Relative Bioavailability and Tolerability of Various Experimental Formulations of BIBV 308 SE in Healthy Subjects

NCT02223000

Phase 1 Completed 9 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Comparative pharmacokinetics of 2-4 experimental modified release formulations and oral solution of BIBV 308 SE following multiple doses, tolerability

Timeline

Start
1998-03
Primary completion
1998-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Terbogrel Small molecule 50 mg Oral

Indications

No indication recorded.